Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Literature DB >> 15860848

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Michael S Ewer¹, Scott M Lippman.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 15860848 DOI： 10.1200/JCO.2005.05.827

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

159 in total

Review 1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: Intern Emerg Med Date: 2011-12-13 Impact factor: 3.397

Review 2. [Comorbidity oriented oncology - an overview].

Authors: Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal: Wien Klin Wochenschr Date: 2010-04 Impact factor: 1.704

Review 3. An update on cardio-oncology.

Authors: Joerg Herrmann; Amir Lerman
Journal: Trends Cardiovasc Med Date: 2014-07-22 Impact factor: 6.677

4. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.

Authors: Onder Tonyali; Ugur Coskun; Nur Sener; Mevlude Inanc; Tulay Akman; Berna Oksuzoglu; Nuriye Yildirim Ozdemir; Dogan Yazilitas; Mustafa Benekli; Aytug Uner; Deniz Yamac; Umut Demirci; Ramazan Yildiz; Halit Karaca; Olcun Umit Unal; Oznur Bal; Mahmut Gumus; Suleyman Buyukberber
Journal: J Cancer Res Clin Oncol Date: 2012-08-10 Impact factor: 4.553

Review 5. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.

Authors: Howard Fingert; Mary Varterasian
Journal: AAPS J Date: 2006-03-10 Impact factor: 4.009

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Review 1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.

Review 2. [Comorbidity oriented oncology - an overview].

Review 3. An update on cardio-oncology.

4. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.

Review 5. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.

6. Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic.

7. Anthracycline cardiotoxicity: from bench to bedside.

Review 8. Exercise training in cancer related cardiomyopathy.

Review 9. Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics.

10. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.